Clinical Trial: A Study of WD-890 in Participants With Moderate-to-severe Plaque Psoriasis

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06912165) titled 'A Study of WD-890 in Participants With Moderate-to-severe Plaque Psoriasis' on March 28.

Brief Summary: Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Study Start Date: Dec. 31, 2024

Study Type: INTERVENTIONAL

Condition: Brief Description of Focus of Study

Intervention: DRUG: WD-890 tablet

Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG: WD-890 tablet

Participants will receive WD-890 Dose 2 QD and placebo fro...